A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor Xenografts
Open Access
- 3 August 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 80 (19), 4278-4287
- https://doi.org/10.1158/0008-5472.can-19-3850
Abstract
Advanced ovarian cancers are a leading cause of cancer-related death in women and are currently treated with surgery and chemotherapy. This standard of care is often temporarily successful but exhibits a high rate of relapse, after which, treatment options are few. Here we investigate whether biomarker-guided use of multiple targeted therapies, including small molecules and antibody–drug conjugates, is a viable alternative. A panel of patient-derived ovarian cancer xenografts (PDX), similar in genetics and chemotherapy responsiveness to human tumors, was exposed to 21 monotherapies and combination therapies. Three monotherapies and one combination were found to be active in different subsets of PDX. Analysis of gene expression data identified biomarkers associated with responsiveness to each of the three targeted therapies, none of which directly inhibits an oncogenic driver. While no single treatment had as high a response rate as chemotherapy, nearly 90% of PDXs were eligible for and responded to at least one biomarker-guided treatment, including tumors resistant to standard chemotherapy. The distribution of biomarker positivity in The Cancer Genome Atlas data suggests the potential for a similar precision approach in human patients. This study exploits a panel of patient-derived xenografts to demonstrate that most ovarian tumors can be matched to effective biomarker-guided treatments.Other Versions
Funding Information
- NCI (U54-CA225088)
- NIGMS (T32-GM007753)
This publication has 47 references indexed in Scilit:
- The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challengesChinese Journal of Cancer, 2015
- The Use of Patient-Derived Xenograft (PDX) Models to Predict Patient Response in Non-Small Cell Lung Cancer (NSCLC)International Journal of Radiation Oncology*Biology*Physics, 2014
- Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer ResearchCancer Discovery, 2014
- Molecular correlates of platinum response in human high‐grade serous ovarian cancer patient‐derived xenograftsMolecular Oncology, 2014
- Patient-Derived Tumor Xenografts: Transforming Clinical Samples into Mouse ModelsCancer Research, 2013
- A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft ModelsCancer Research, 2013
- Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cellsNucleic Acids Research, 2012
- Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomesNature Medicine, 2011
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2003